Stable glucagon - Albireo Pharma

Drug Profile

Stable glucagon - Albireo Pharma

Alternative Names: BIOD-961; BIOD-962; BIOD-Stable Glucagon; EZMix; EZMix-GEM program; Glucagon rescue GEM; Glucagon rescue Glucagon Emergency Management program; Injectable stable glucagon - Albireo Pharma

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator Biodel
  • Developer Albireo Pharma
  • Class Antihypoglycaemics; Pancreatic hormones
  • Mechanism of Action Glucagon receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypoglycaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Hypoglycaemia

Most Recent Events

  • 16 Mar 2015 Pharmacokinetic, pharmacodynamic and adverse events data from a phase I trial released by Biodel
  • 01 Mar 2015 Biodel completes phase I trial in Hypoglycaemia (In volunteers) in USA (NCT02403648)
  • 04 Dec 2014 Phase-I clinical trials in Hypoglycaemia (In volunteers) in USA (IM, SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top